INFLUENZA A&B TESTS

A rapid qualitative test that detects Influenza type A and type B antigens directly from nasal swab, nasopharyngeal swab, and nasal aspirate/wash specimens. For professional and laboratory use only. For in vitro diagnostic use only. Rx Only. For use with MFR # 181-36025

CLIA Complexity: Moderate Complexity when used with Nasal Wash/Aspirate Samples. CLIA Waived when used with Nasal and Nasopharyngeal Swabs.

INTENDED USE
McKesson Consult® Influenza A&B Test is an in vitro rapid qualitative test that detects influenza type A and type B nucleoprotein antigens directly from nasal swab, nasopharyngeal swab, and nasopharyngeal aspirate/wash specimens obtained from patients with signs and symptoms of respiratory infection. It is intended to aid in the rapid differential diagnosis of influenza A and B viral infections.

Negative test results are presumptive and it is recommended these results be confirmed by viral culture. Negative results do not preclude influenza virus infection and should not be used as the sole basis for treatment or other management decisions.

The test is intended for professional and laboratory use.

Performance characteristics for influenza were established during the 2007-2009 influenza seasons when influenza A viruses A/New Caledonia/20/99 (H1N1), A/Solomon Islands/3/2006 (H1N1), A/Brisbane/59/2007 (H1N1), A/California/07/2009 (H1N1), A/Wisconsin/67/2005 (H3N2), A/Brisbane/10/2007 (H3N2) and influenza B viruses B/Ontario/01/2005, B/Florida/4/2006, B/Brisbane/60/2008 were the predominant influenza viruses in circulation according to the Flu Activity & Surveillance report by CDC. Performance characteristics may vary against other emerging influenza viruses.

If infection with a novel influenza virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent influenza viruses and sent to state or local health department for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens.

SUMMARY AND EXPLANATION
Influenza is a highly contagious acute viral infection of the respiratory tract. It is a communicable disease easily transmitted from person to person through aerosol droplets excreted when sneezing and coughing. Common symptoms include high fever, chills, headache, cough, sore throat and malaise. The type A influenza virus is more prevalent and is the primary pathogen associated with serious epidemics. The type B virus causes a disease that is generally not as severe as that caused by the type A virus.

An accurate diagnosis of influenza based on clinical symptoms is difficult because the initial symptoms of influenza are similar to those of numerous other illnesses. Therefore, it can be confirmed only by laboratory diagnostic testing. Early differential diagnosis of influenza type A or type B can allow for proper treatment with appropriate antiviral therapy while reducing the incidence of inappropriate treatment with antibiotics. Early diagnosis and treatment is of particular value in a clinical setting where accurate diagnosis can assist the healthcare professional with management of influenza patients who are at risk for complications.

McKesson Consult Influenza A&B Tests are a rapid immunoassay to be used as an aid for the differential diagnosis of influenza type A and type B.

PRINCIPLE OF PROCEDURE
McKesson Consult Influenza A&B Tests utilize the chemical extraction of viral antigens followed by solid-phase immunoassay technology for the detection of extracted antigen, influenza A and/or B. In the test procedure, a specimen is collected and placed for one minute into the Extraction Well of the test cassette containing extraction solution, during which time antigen is extracted from disrupted virus particles. The test cassette is then raised, tapped and laid back down onto a level surface to allow the solution in the Extraction Well to migrate through the pads containing detector antibodies conjugated to gold dye and then through the test membrane. If influenza antigens are present in the specimen, they will react with anti-influenza antibody coupled to gold dye particles, migrate through the membrane as antigen-antibody-dye complexes, bind to the immobilized anti-influenza antibody on the membrane, and generate a colored line in the Test Line position (A and/or B). The rest of the sample and unbound/bound dye complexes continue to migrate to the Control line position (C), where antibody to the anti-influenza antibody is immobilized, and forms the Control line. Formation of the Control line serves as an internal control to demonstrate that antibodies in the dye pad have been hydrated and that sufficient sample has been applied to allow for migration to the Test line and beyond. If the Control line does not appear within the designated incubation time, the result is invalid and the test should be repeated.

McKesson Consult Influenza A&B Tests have two Test lines, one for influenza A and one for influenza B. The two Test lines allow for the separate and differential identification of influenza A and/or B from the same specimen. If either Test line appears in the test result window, together with the Control line, the test result is positive for influenza.

REAGENTS

Materials Provided

• McKesson Consult Influenza A&B test cassettes (25): The test strip in each cassette contains mouse monoclonal antibodies to nucleoprotein (NP) of influenza A and influenza B. The cassette is individually pouched.
• Extraction Reagent in capsules (25): For use with swab samples, 300 µL of Phosphate buffer with detergents and preservative
• Positive Control Swab (1): Influenza A and B antigens (non-infective recombinant nucleoprotein)
• Negative Control Swab (1): Inactivated Group B Streptococcus antigen (non-infective)
• Sterile Swabs (25): For swab samples
• Procedure Card (1)

Materials Required, But Not Provided

For Aspirate Samples only [available separately: MFR # 181-36026]

• Extraction Reagent in a bottle (5 mL): Phosphate buffer with detergents and 0.09% sodium azide
• Disposable Transfer Pipettes (50): Buffer and sample transfer
• Procedure card for aspirate samples

For All Sample types:

• Timer
• Latex gloves

PRECAUTIONS/WARNINGS

• For in vitro diagnostic use only.
• Do not use after the expiration date.
• Use only the swabs provided for collecting swab samples. Other swabs may not work properly.
• Two forms of Extraction Reagent are available. Use Extraction Reagent in capsules to test swab samples, and Extraction Reagent in a bottle to test nasopharyngeal wash/aspirate samples.
• Do not smoke, eat or drink in areas in which specimens or kit reagents are handled.
• Extraction Reagent is slightly caustic. Avoid contact with eyes, sensitive mucous membranes, cuts, abrasions, etc. If the reagent comes in contact with skin or eyes, flush with a large volume of water.
• Wear disposable gloves while handling kit reagents or specimens and thoroughly wash hands afterwards.
• All specimens should be handled as if they are capable of transmitting disease. Observe established precautions against microbiological hazards throughout all procedures and follow the standard procedures for proper disposal of specimens and test materials.
• The McKesson Consult Influenza A&B test cassette should remain in its original sealed pouch until ready for use. Do not use the test if the seal is broken or the pouch is damaged.
• Performance characteristics for influenza A were established when influenza A/H3 and A/H1 were the predominant influenza A viruses in circulation. When other influenza A viruses emerge, performance characteristics may vary.
• If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent influenza viruses and sent to state or local health departments for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens.

STORAGE AND STABILITY
The McKesson Consult Influenza A&B Test may be stored at 35-86°F (2-30°C) in the original sealed pouch, away from direct sunlight. Kit contents are stable until the expiration date printed on the pouch or box.

SPECIMEN COLLECTION AND PREPARATION
• Inadequate or inappropriate specimen collection, storage, and transport are likely to yield false negative test results. Training in specimen collection is highly recommended because of the importance of specimen quality.
• To collect nasopharyngeal or nasal swab specimens, the swab provided in the McKesson Consult Influenza A&B test kit should only be used.
• Using 2.5 mL of sterile saline solution is recommended to collect wash/aspirate specimens.
• Use fresh samples for best performance. Freshly collected specimens should be tested immediately. If necessary, aspirate specimens may be stored for up to 8 hrs at room temperature or up to 24 hrs at 2-8°C, and swab samples for up to 4 hrs at room temperature or up to 8 hrs at 2-8°C. Aspirate samples can be frozen for up to 7 days.
• If transport of the samples is required, the following transport media have been tested and shown not to interfere with the performance of the test.

BD™ Universal Viral Transport medium Saline solution
BD™ Eswab collection kit Puritan Amies Transport medium
Veal Infusion Broth Puritan UTM medium
Copan UTM-RT medium Hank’s Balanced Salt Solution
Tryptose Phosphate Broth Bartel ViraTrans™ medium
PBS PBS + 0.5% BSA
M4 medium M5 medium M6 medium

Flu A&B Specimen Collection Procedures
Good sample collection is the most important first step for an accurate test result. Therefore, follow below instruction carefully to obtain as much secretion as possible.

Nasopharyngeal Wash Specimen:
Position the patient comfortably in a sitting position, with the neck slightly hyper-extended. Prior to the procedure, have the patient blow their nose. Using a sterile syringe, introduce 2.5 ml of sterile saline into one nostril. If possible, have the patient retain the saline for a few seconds. Place specimen container directly under the nose with slight pressure on the upper lip. Tilt the head forward and allow the fluid to flow into the specimen container. Repeat the procedure on other nostril, collecting fluid into the same container.

Nasopharyngeal Aspirate Specimen:
Position the patient comfortably in a sitting position, with the neck slightly hyper-extended. Prior to the procedure, have the patient blow their nose. Using a sterile syringe, introduce 2.5 ml of sterile saline into one nostril. If possible, have the patient retain the saline for a few seconds. Place specimen container directly under the nose with slight pressure on the upper lip. Tilt the head forward and allow the fluid to flow into the specimen container. Repeat the procedure on other nostril, collecting fluid into the same container.

Swab Sample Procedure
1. Draw nasal wash or nasopharyngeal aspirate sample to the first (lowest) mark of the graduated transfer pipette.
2. Squeeze the Extraction Reagent capsule to dispense all of the solution into the Extraction Well of the test cassette.
3. Insert the specimen swab on the Swab Stand in the Extraction Well.
4. Incubate 1 minute with the swab in Extraction Well.
5. Rotate swab 3 times to mix the specimen.
6. Raise the cassette upright (see picture).
7. Let it stand for 1-2 seconds. Gently tap the cassette to ensure that the liquid flows into the hole.
8. Lay the cassette back down onto the flat surface. Start timing.
9. Read test results at 10-15 minutes. Confirm negative results at 15 minutes.

Nasopharyngeal Wash/Aspirate Sample Procedure (Purchase of MFR # 181-36026 required)
1. Draw nasal wash or nasopharyngeal aspirate sample to the first (lowest) mark of the graduated transfer pipette.
2. Dispense the entire sample in the transfer pipette into the Extraction Well of the test cassette.
3. Remove the cap from the Extraction Reagent bottle.
4. Using a new transfer pipette, draw Extraction Reagent Solution to the first (lowest) mark.
5. Dispense all of the solution in the transfer pipette into the Extraction Well of the test cassette.
6. Incubate 1 minute. Re-cap the Extraction Reagent bottle.
7. Raise the test cassette upright (see picture).
8. Let it stand for 1-2 seconds. Gently tap the cassette to ensure that the liquid flows into the hole.
9. Lay the cassette back down onto the flat surface. Start timing.
10. Read test results at 10-15 minutes. Confirm negative results at 15 minutes.

Procedural Notes
• The test procedure below must be followed to obtain accurate and reproducible results.
• Reagents, specimens, and cassettes must be at room temperature (18-30°C) for testing.
• Do not open the foil pouch until you are ready to perform the test.
• Several tests may be run at one time.
• Label the cassette with the patient identification or control to be tested.
• Place test cassette on a level surface.
• The test procedure below must be followed to obtain accurate and reproducible results.
• Reagents, specimens, and cassettes must be at room temperature (18-30°C) for testing.
• Do not open the foil pouch until you are ready to perform the test.
• Several tests may be run at one time.
• Label the cassette with the patient identification or control to be tested.
• Place test cassette on a level surface.
• Several tests may be run at one time.
• Label the cassette with the patient identification or control to be tested.
• Place test cassette on a level surface.

Flu A&B Specimen Collection Procedures
Good sample collection is the most important first step for an accurate test result. Therefore, follow below instruction carefully to obtain as much secretion as possible.

Nasopharyngeal Wash Specimen:
Position the patient comfortably in a sitting position, with the neck slightly hyper-extended. Prior to the procedure, have the patient blow their nose. Using a sterile syringe, introduce 2.5 ml of sterile saline into one nostril. If possible, have the patient retain the saline for a few seconds. Place specimen container directly under the nose with slight pressure on the upper lip. Tilt the head forward and allow the fluid to flow into the specimen container. Repeat the procedure on other nostril, collecting fluid into the same container.

Nasopharyngeal Aspirate Specimen:
Position the patient comfortably in a sitting position, with the neck slightly hyper-extended. Prior to the procedure, have the patient blow their nose. Using a sterile syringe, introduce 2.5 ml of sterile saline into one nostril. If possible, have the patient retain the saline for a few seconds. Place specimen container directly under the nose with slight pressure on the upper lip. Tilt the head forward and allow the fluid to flow into the specimen container. Repeat the procedure on other nostril, collecting fluid into the same container.

Swab Sample Procedure
1. Draw nasal wash or nasopharyngeal aspirate sample to the first (lowest) mark of the graduated transfer pipette.
2. Squeeze the Extraction Reagent capsule to dispense all of the solution into the Extraction Well of the test cassette.
3. Insert the specimen swab on the Swab Stand in the Extraction Well.
4. Incubate 1 minute with the swab in Extraction Well.
5. Rotate swab 3 times to mix the specimen.
6. Raise the cassette upright (see picture).
7. Let it stand for 1-2 seconds. Gently tap the cassette to ensure that the liquid flows into the hole.
8. Lay the cassette back down onto the flat surface. Start timing.
9. Read test results at 10-15 minutes. Confirm negative results at 15 minutes.

Nasopharyngeal Wash/Aspirate Sample Procedure (Purchase of MFR # 181-36026 required)
1. Draw nasal wash or nasopharyngeal aspirate sample to the first (lowest) mark of the graduated transfer pipette.
2. Dispense the entire sample in the transfer pipette into the Extraction Well of the test cassette.
3. Remove the cap from the Extraction Reagent bottle.
4. Using a new transfer pipette, draw Extraction Reagent Solution to the first (lowest) mark.
5. Dispense all of the solution in the transfer pipette into the Extraction Well of the test cassette.
6. Incubate 1 minute. Re-cap the Extraction Reagent bottle.
7. Raise the test cassette upright (see picture).
8. Let it stand for 1-2 seconds. Gently tap the cassette to ensure that the liquid flows into the hole.
9. Lay the cassette back down onto the flat surface. Start timing.
10. Read test results at 10-15 minutes. Confirm negative results at 15 minutes.
**SWAB SAMPLE PROCEDURE**

1. Tear the tab off the Extraction Reagent Capsule and dispense entire contents into the Extraction Well.

2. Insert the specimen swab in the Swab Stand.
   - Spin swab 3 times to mix the specimen.
   - Let stand 1 minute.
   - Spin swab 3 times again.

3. Discard the swab. Raise the cassette upright and let stand 1-2 seconds.

4. Gently tap cassette to ensure the liquid flows into the hole.

   Then, lay the cassette back down.

**Start timing.**

5. Read test results at 10–15 minutes. Confirm negative results at 15 minutes.

---

**NASOPHARYNGEAL WASH/ASPIRATES SAMPLE PROCEDURE (PURCHASE OF MFR # 181-36026 REQUIRED)**

1. Draw nasal wash or nasal aspirate sample to the first (lowest) mark of the graduated transfer pipette.

2. Dispense the entire sample in the transfer pipette into the Extraction Well of the test cassette.

3. Remove the cap from the Extraction Reagent bottle. Using a new transfer pipette, draw Extraction Reagent Solution to the first (lowest) mark.

4. Dispense all of the solution in the transfer pipette into the Extraction Well of the test cassette.

5. Let stand 1 minute. Re-cap the Extraction Reagent bottle.

6. Raise the cassette upright and let stand 1-2 seconds.

7. Gently tap cassette to ensure the liquid flows into the hole.

   Then, lay the cassette back down.

**Start timing.**

8. Read test results at 10-15 minutes. Confirm negative results at 15 minutes.
**INTERPRETATION OF RESULTS**

**Positive:** A reddish purple Control line (C position) and a reddish purple Test line (A or B position) indicate that Influenza A or B antigen has been detected. Lines at the A and C positions indicate the presence of Influenza A viral antigen, and lines at the B and C positions indicate the presence of Influenza type B viral antigen in the sample. A positive result does not rule out co-infections with other pathogens or identify any specific influenza virus subtype. Determination of a positive result can be made as soon as both a visible Test line (either A or B) and Control line appear.

**Note:** The Test line (reddish purple line) may vary in shade and intensity (light or dark, weak or strong) depending on the concentration of antigen detected. The intensity of the Control line should not be compared to that of the Test line for the interpretation of the test result. Even a light or faint Test line must be interpreted as a positive result.

**Negative:** Only a reddish purple Control line (C position), with no Test line at the A or B position, indicates that Influenza A or B antigen has not been detected. A negative result does not exclude influenza viral infection. Determination of negative results should not be made before 15 min.

**Invalid:** A reddish purple line should always appear at the Control line position (C). If a line does not form at the Control line position in 15 minutes, the test result is invalid and the test should be repeated with a new McKesson Consult Influenza A&B Test cassette.

**NOTE:** Co-infection with Influenza A and B is rare. McKesson Consult Influenza A&B “dual positive” clinical specimens (Influenza A and Influenza B positive) should be re-tested. Repeatable influenza A and B “dual positive” results should be confirmed by cell culture or PCR testing before reporting results.

**LIMITATIONS**

- A negative test result does not exclude infection with influenza A or B. Therefore, the results obtained with the McKesson Consult Influenza A&B Test should be used in conjunction with clinical findings to make an accurate diagnosis. Additional testing is required to differentiate any specific influenza A and B subtypes or strains, in consultation with state or local public health departments.
- This test detects both viable (live) and non-viable influenza A and B. Test performance depends on the amount of virus (antigen) in the specimen and may or may not correlate with cell culture results performed on the same specimen.
- McKesson Consult Influenza A&B Test uses highly target specific monoclonal antibodies. As in most immunoassays, it may fail to detect, or detect with less sensitivity, influenza A viruses that have undergone minor amino acid changes in the target epitope region.
- Performance of the McKesson Consult Influenza A&B Test has not been established for monitoring antiviral treatment of influenza.
- Children tend to shed virus more abundantly and for longer periods of time than adults. Therefore, testing specimens from adults will result in lower sensitivity than testing specimens from children.
- Positive and negative predictive values are highly dependent on prevalence. False negative test results are more likely during peak activity when prevalence of disease is high. False positive test results are more likely during periods of low influenza activity when prevalence is moderate to low.
- Individuals who received nasally administered influenza A vaccine may produce positive test results for up to three days after vaccination.
- The performance of this assay has not been evaluated for use in patients without signs and symptoms of respiratory infection.
- This test cannot rule out diseases caused by other bacterial or viral pathogens.
- The performance of this test has not been evaluated for sample types other than those specified in the Intended Use.
- The performance of this test has not been evaluated for immunocompromised individuals.
- The McKesson Consult Influenza A&B Test can distinguish between influenza A and B viruses, but it cannot differentiate influenza subtypes.

**USER QUALITY CONTROL**

**Internal Quality Control:**

Each McKesson Consult Influenza A&B Test cassette has built-in controls. The Control line at the C position can be considered as an internal positive procedural control; i.e., a proper amount of sample was used, sample was properly added to the Extraction Well, sample migrated properly, and the reagent system worked properly. A distinct reddish-purple Control line should always appear if the test has been performed correctly. If the Control line does not appear, the test result is invalid and a new test should be performed. If the problem persists, contact Technical Support at 1-800-526-2125. A clear background in the Test Result Window is considered an internal negative procedural control. If the test is performed correctly and the McKesson Consult Influenza A&B Test cassette is working properly, the background in the Test Result Window will be clear, providing a distinct result.

**External Quality Control:**

Good laboratory practice includes the use of external controls to ensure proper kit performance. It is recommended that external control testing be performed with each new operator and before using a new lot or shipment of McKesson Consult Influenza A&B Test kits to confirm the expected Q.C. results, using the external controls provided in the kit. The frequency of additional Q.C. tests should be determined according to your laboratory’s standard Q.C. procedures and local, State and Federal regulations or accreditation requirements. Upon confirmation of the expected results, the kit is ready for use with patient specimens. If external controls do not perform as expected, do not use the test results. Repeat the tests or contact Technical Support at 1-800-526-2125. The built-in reddish purple Control line indicates only the integrity of the test cassette and proper fluid flow.

The McKesson Consult Influenza A&B Test kit contains two control swabs. Test the control swabs in the same manner as patient specimens. When the positive control is tested, reddish purple lines appear at the C, A and B positions. When the negative control is tested, a reddish purple line appears at the C position only. If the controls do not perform as expected, do not report patient results.

The use of positive and negative controls from other commercial kits has not been established with McKesson Consult Influenza A&B Test.

**EXPECTED VALUES**

The prevalence of influenza varies every year and the rate of positives in influenza testing varies depending on many factors, including the specimen collection method, the test method used, the disease prevalence, and the geographic location. The prevalence observed with reference tests (culture and PCR) during the 2007-2009 clinical study for McKesson Consult Influenza A&B Test was 27% for influenza A and 11% for influenza B.

**PERFORMANCE CHARACTERISTICS**

**Clinical Performance**

A prospective clinical study was conducted from January 2007 to March 2008 and during March and April 2009 to determine the performance of McKesson Consult Influenza A&B Test for aspirate, nasopharyngeal swab, and nasal swab specimens.

The samples were collected at 5 sites in the USA from patients who visited physicians’ offices and clinics with signs and symptoms of respiratory infection during the study period. All collected samples were tested with McKesson Consult Influenza A&B Test, and were cultured. The culture was used as the reference method. The total number of patients tested was 862, of which 30% were 5 and younger, 30% were 6-21 years old, and the rest were older than 21. Forty eight (48) percent were male and 52% were female. In addition to the prospective clinical study, eighty (80) positive influenza A or B frozen archived samples were tested with McKesson Consult Influenza A&B Tests.

The combined data from all sites of the prospective study are presented in the tables below.

The samples that produced discrepant results between McKesson Consult Influenza A&B Tests and viral culture were further analyzed with proFLU+ by Prodesse [real time RT-PCR, PCR hereafter]. These results are presented in the footnote below each table.
Nasopharyngeal Aspirate Sample

<table>
<thead>
<tr>
<th>McKesson Consult</th>
<th>Flu A Positive</th>
<th>Flu A Negative</th>
<th>Total</th>
<th>Performance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flu A Positive</td>
<td>41</td>
<td>30*</td>
<td>71</td>
<td>Sensitivity: 95.3% 95% CI: 92.1-98.5%</td>
</tr>
<tr>
<td>Flu A Negative</td>
<td>2**</td>
<td>180</td>
<td>182</td>
<td>Specificity: 85.7% 95% CI: 83.3-88.1%</td>
</tr>
<tr>
<td>Total</td>
<td>43</td>
<td>210</td>
<td>253</td>
<td></td>
</tr>
</tbody>
</table>

*Of 30 discrepant results, 22 were positive by both McKesson Consult and PCR  
**Of 2 discrepant results, 1 was negative by both McKesson Consult and PCR

Flu A Positive 41 30* 71  
Flu A Negative 2** 180 182  
Total 43 210 253

Reference (Virus Culture) Results

<table>
<thead>
<tr>
<th>McKesson Consult</th>
<th>Flu B Positive</th>
<th>Flu B Negative</th>
<th>Total</th>
<th>Performance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flu B Positive</td>
<td>11</td>
<td>6*</td>
<td>17</td>
<td>Sensitivity: 91.6% 95% CI: 83.6-99.6%</td>
</tr>
<tr>
<td>Flu B Negative</td>
<td>1**</td>
<td>235</td>
<td>236</td>
<td>Specificity: 97.5% 95% CI: 96.5-98.5%</td>
</tr>
<tr>
<td>Total</td>
<td>12</td>
<td>241</td>
<td>253</td>
<td></td>
</tr>
</tbody>
</table>

*Of 6 discrepant results, all 6 were positive by McKesson Consult and by PCR  
**The discrepant sample was positive by PCR

Flu B Positive 11 6* 17  
Flu B Negative 1** 235 236  
Total 12 241 253

Nasopharyngeal Swab Sample

<table>
<thead>
<tr>
<th>McKesson Consult</th>
<th>Flu A Positive</th>
<th>Flu A Negative</th>
<th>Total</th>
<th>Performance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flu A Positive</td>
<td>26</td>
<td>51*</td>
<td>77</td>
<td>Sensitivity: 89.6% 95% CI: 84.0-95.2%</td>
</tr>
<tr>
<td>Flu A Negative</td>
<td>3**</td>
<td>171</td>
<td>174</td>
<td>Specificity: 77.0% 95% CI: 74.2-79.8%</td>
</tr>
<tr>
<td>Total</td>
<td>29</td>
<td>222</td>
<td>251</td>
<td></td>
</tr>
</tbody>
</table>

*Of 51 discrepant results, 42 were positive by both McKesson Consult and PCR  
**Of 3 discrepant results, 1 was negative by both McKesson Consult and PCR

Flu A Positive 26 51* 77  
Flu A Negative 3** 171 174  
Total 29 222 251

Flu A Positive 33 0 33 100%  
Flu A Negative 0 30 30 100%  
Total 33 30 63

Aspirate Sample

<table>
<thead>
<tr>
<th>McKesson Consult</th>
<th>Flu A Positive</th>
<th>Flu A Negative</th>
<th>Total</th>
<th>Agreement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flu A Positive</td>
<td>50</td>
<td>0</td>
<td>50</td>
<td>100%</td>
</tr>
<tr>
<td>Flu A Negative</td>
<td>0</td>
<td>30</td>
<td>30</td>
<td>100%</td>
</tr>
<tr>
<td>Total</td>
<td>50</td>
<td>30</td>
<td>80</td>
<td></td>
</tr>
</tbody>
</table>

Reference (Virus Culture) Results

<table>
<thead>
<tr>
<th>McKesson Consult</th>
<th>Flu B Positive</th>
<th>Flu B Negative</th>
<th>Total</th>
<th>Agreement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flu B Positive</td>
<td>14</td>
<td>40*</td>
<td>54</td>
<td></td>
</tr>
<tr>
<td>Flu B Negative</td>
<td>3**</td>
<td>301</td>
<td>304</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>17</td>
<td>341</td>
<td>358</td>
<td></td>
</tr>
</tbody>
</table>

*Of 40 discrepant results, 19 were positive by both McKesson Consult and PCR  
**Of 3 discrepant results, 1 was negative by both McKesson Consult and PCR

Flu B Positive 14 40* 54  
Flu B Negative 3** 301 304  
Total 17 341 358

Archived Sample Test Results

Eighty (80) frozen archived samples originally obtained from influenza positive patients visiting Columbia NY Presbyterian Hospital and confirmed as positive for either Influenza A or Influenza B by viral culture were tested with McKesson Consult Influenza A&B Tests. The tables below present test results with archived samples.

<table>
<thead>
<tr>
<th>Reference (Virus Culture) Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>McKesson Consult</td>
</tr>
<tr>
<td>------------------</td>
</tr>
<tr>
<td>Flu A Positive</td>
</tr>
<tr>
<td>Flu A Negative</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

Aspirate Sample

<table>
<thead>
<tr>
<th>McKesson Consult</th>
<th>Flu B Positive</th>
<th>Flu B Negative</th>
<th>Total</th>
<th>Agreement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flu B Positive</td>
<td>30</td>
<td>0</td>
<td>30</td>
<td>100%</td>
</tr>
<tr>
<td>Flu B Negative</td>
<td>0</td>
<td>50</td>
<td>50</td>
<td>100%</td>
</tr>
<tr>
<td>Total</td>
<td>30</td>
<td>50</td>
<td>80</td>
<td></td>
</tr>
</tbody>
</table>
### Analytical Sensitivity

**Limit of Detection (LOD)**

The LODs were determined for each of the two strains selected from the influenza type A and type B strains listed in the analytical inclusivity (sensitivity) section below. The sensitivity level of each selected viral strain established in the analytical inclusivity (sensitivity) study was tested 60 times to confirm the sensitivity level as LOD level, which gives 95% detection rate. All four viral strains tested were detected 96.7% of the time in 60 replicates.

### Analytical Inclusivity

The analytical inclusivity (sensitivity) was established for a total of 49 influenza strains: 34 strains of influenza A type and 15 strains of influenza B type. The results are shown in the tables below.

#### Influenza A Strains

<table>
<thead>
<tr>
<th>Influenza Type</th>
<th>Viral Strain #</th>
<th>TCID50/mL</th>
<th>EID50/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>A/Anhui/1/2013 (H7N9)</td>
<td>7.94 x 10^6</td>
<td>A/Texas/50/2012</td>
<td>2.03 x 10^6</td>
</tr>
<tr>
<td>A/Velnam/1194/2004 (H5N1)</td>
<td>1.60 x 10^6</td>
<td>A/California/07/2009</td>
<td>1.01 x 10^6</td>
</tr>
<tr>
<td>A/Anhui/01/2005 (H5N1)</td>
<td>1.60 x 10^6</td>
<td>A/Washington/24/2012</td>
<td>2.02 x 10^6</td>
</tr>
<tr>
<td>A/Northern/Pintail/ Washington/40964/2014 (H5N2)</td>
<td>8.04 x 10^5</td>
<td>B/Brisbane/60/2008</td>
<td>3.19 x 10^5</td>
</tr>
<tr>
<td>A/Gyrfalcon / Washington/41086/2014 (H5N8)</td>
<td>2.03 x 10^5</td>
<td>B/Montana/05/2012</td>
<td>4.02 x 10^5</td>
</tr>
<tr>
<td>A/Brisbane 59/2007</td>
<td>1.01 x 10^5</td>
<td>B/Wisconsin/1/2010</td>
<td>2.54 x 10^5</td>
</tr>
<tr>
<td>A/Fujian Gulou /1986/2009</td>
<td>8.06 x 10^5</td>
<td>B/Massachusetts /22/2012</td>
<td>1.01 x 10^6</td>
</tr>
<tr>
<td>A/Perth/16/2009</td>
<td>2.54 x 10^5</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The performance of McKesson Consult Influenza A&B Tests were evaluated with nasal and nasopharyngeal swab samples obtained from patients infected with the 2009 H1N1 influenza virus consisting of sixty six (66) frozen clinical Nasal and Nasopharyngeal samples that had previously tested positive for 2009 H1N1 by FDA-cleared CDC RT-PCR test. The McKesson Consult Influenza A&B Test detected 71% (47/66) of the CDC RT-PCR test positive specimens. The detection rate was 91% with the higher titered specimens and 38% with the lower titered specimens.

**ANALYTICAL SPECIFICITY**

**Cross-reactivity**

The potential cross-reactivity of the non-influenza respiratory pathogens and other microorganisms with which the majority of the population may be infected was tested using the McKesson Consult Influenza A&B Test at medically relevant levels, 10^6 cfu/mL for bacteria and 10^5 pfu/mL for non-flu viruses. None of the organisms or viruses listed in the table below gave a positive result with McKesson Consult Influenza A&B Tests at the tested concentration.

### Viruses Tested

<table>
<thead>
<tr>
<th>Viruses Tested</th>
<th>Concentration Tested</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adenovirus**</td>
<td>Measles**</td>
</tr>
<tr>
<td>Human coronavirus**</td>
<td>Human metapneumovirus**</td>
</tr>
<tr>
<td>Cytomegalovirus**</td>
<td>Mumps virus**</td>
</tr>
<tr>
<td>Enterovirus**</td>
<td>Respiratory syncytial virus; Type B*</td>
</tr>
<tr>
<td>Epstein Barr Virus**</td>
<td>Rhinovirus; Type 1A**</td>
</tr>
<tr>
<td>Human parainfluenza; Type 1, 2 and 3*</td>
<td></td>
</tr>
</tbody>
</table>

*In the study the virus was confirmed using FDA approved immuno-fluorescence assay.

**In the study the virus was confirmed using commercially available PCR (not approved by FDA).

### Bacteria Tested

<table>
<thead>
<tr>
<th>Bacteria Tested</th>
<th>Concentration Tested</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bordetella pertussis</td>
<td>Mycoplasma pneumoniae</td>
</tr>
<tr>
<td>Chlamydia pneumoniae</td>
<td>Neisseria meningitides</td>
</tr>
<tr>
<td>Corynebacterium sp.</td>
<td>Neisseria sp.</td>
</tr>
<tr>
<td>Escherichia coli</td>
<td>Pseudomonas aeruginosa</td>
</tr>
<tr>
<td>Hemophilus influenzae</td>
<td>Staphylococcus aureus: Protein A Producer</td>
</tr>
<tr>
<td>Lactobacillus sp.</td>
<td>Staphylococcus epidermidis</td>
</tr>
<tr>
<td>Legionella sp.</td>
<td>Streptococcus pneumoniae</td>
</tr>
<tr>
<td>Moraxella catarrhalis</td>
<td>Streptococcus pyogenes</td>
</tr>
<tr>
<td>Mycobacterium tuberculosis avirulent</td>
<td>Streptococcus salivarius</td>
</tr>
</tbody>
</table>

### Interference

The interference study was conducted using medically relevant concentrations of the potentially interfering substances listed below with two strains each of influenza type A and type B to assess the potential interference of the substances on the performance of the McKesson Consult Influenza A&B Test. The test was conducted by spiking each substance into samples containing the lowest detectable virus level of influenza Type A or Type B for the positive interference testing and into samples without influenza virus for the negative interference testing. Each substance had no inhibitory effect on the McKesson Consult Influenza A&B Test at the concentration listed in the table below.

### CLIA WAIVER STUDY

#### Clinical Study at CLIA Waived Sites

To evaluate the expected performance of the McKesson Consult Influenza A&B Test when used by operators at CLIA-waived sites, a prospective clinical study was performed using nasopharyngeal and nasal swab specimens at seven CLIA waived sites (non-laboratory study sites) from December 2014 to May 2016. A total of sixteen operators from seven intended user sites in the USA were involved in the study. All collected samples were tested with both McKesson Consult Influenza A&B Tests and an FDA-cleared NAAT. The total number of samples tested was 455, of which 148 samples were archived samples which were confirmed by PCR as Influenza A or Influenza B.

The combined data from all sites of the prospective study and archived samples are presented in the table below.

### Comparator (PCR) Results

<table>
<thead>
<tr>
<th>Comparator (PCR) Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>McKesson Consult</strong></td>
</tr>
<tr>
<td>Flu A Positive</td>
</tr>
<tr>
<td>Flu A Negative</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

*The total number of Influenza A positive includes 27 archived samples.

<table>
<thead>
<tr>
<th>Comparator (PCR) Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>McKesson Consult</strong></td>
</tr>
<tr>
<td>Flu B Positive</td>
</tr>
<tr>
<td>Flu B Negative</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

*The total number of Influenza B positive includes 121 archived samples.
Performance with near cutoff Concentrations at CLIA Waived Sites

To determine the performance of operators at CLIA waived sites with the McKesson Consult Influenza A&B Test when tested with samples near the cutoff, this study was conducted using a sample panel consisting of high negative ($C_5$), weak positive ($C_{95}$) and moderate positive ($3 \times C_{95}$) samples for influenza type A and B, and samples negative for both flu A and B (true negative). For influenza A and B positive samples, A/Denver/1/57 (H1N1) and B/Maryland/1/59 were used. The testing was performed over a period of 10 days using 90 coded samples for each of 6 operators (True negative: 50, High Negative: 15, Low Positive: 15, Moderate Positive: 10 samples respectively). The results are summarized in below table.

<table>
<thead>
<tr>
<th>Sample</th>
<th>Site 1 (2 operators)</th>
<th>Site 2 (2 operators)</th>
<th>Site 3 (1 operator)</th>
<th>Site 4 (1 operator)</th>
<th>Agreement</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>FluA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>100% (100/100)</td>
<td>97.0% (97/100)</td>
<td>100% (50/50)</td>
<td>100% (50/50)</td>
<td>99.0% (297/300)</td>
<td>97.1% (-99.7%)</td>
</tr>
<tr>
<td>High Negative</td>
<td>96.7% (29/30)</td>
<td>100% (29/29)</td>
<td>93.3% (14/15)</td>
<td>100% (15/15)</td>
<td>97.8% (87/89)</td>
<td>92.2% (-99.4%)</td>
</tr>
<tr>
<td>Low Positive</td>
<td>96.7% (29/30)</td>
<td>100% (30/30)</td>
<td>100% (15/15)</td>
<td>93.3% (14/15)</td>
<td>97.8% (80/90)</td>
<td>92.3% (-99.4%)</td>
</tr>
<tr>
<td>Moderate Positive</td>
<td>100% (20/20)</td>
<td>100% (10/10)</td>
<td>100% (10/10)</td>
<td>100% (60/60)</td>
<td>94.0% (-100%)</td>
<td></td>
</tr>
<tr>
<td>FluB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>100% (100/100)</td>
<td>100% (99/99)</td>
<td>100% (50/50)</td>
<td>100% (50/50)</td>
<td>100% (299/299)</td>
<td>98.7% (-100%)</td>
</tr>
<tr>
<td>High Negative</td>
<td>96.7% (30/30)</td>
<td>93.3% (28/30)</td>
<td>93.3% (14/15)</td>
<td>100% (15/15)</td>
<td>97.8% (88/90)</td>
<td>92.3% (-99.4%)</td>
</tr>
<tr>
<td>Low Positive</td>
<td>96.7% (30/30)</td>
<td>93.3% (28/30)</td>
<td>93.3% (14/15)</td>
<td>100% (15/15)</td>
<td>96.7% (87/90)</td>
<td>90.7% (-99.0%)</td>
</tr>
<tr>
<td>Moderate Positive</td>
<td>100% (20/20)</td>
<td>95.0% (19/20)</td>
<td>100% (10/10)</td>
<td>100% (59/60)</td>
<td>98.3% (-99.7%)</td>
<td></td>
</tr>
</tbody>
</table>

*One test result out of 30 tests was invalid affecting the total number.

REFERENCES
2. WHO recommendations on the use of rapid testing for influenza diagnosis, July 2005.

SYMBOLS

<table>
<thead>
<tr>
<th>SYMBOL</th>
<th>TITLE</th>
<th>STANDARD</th>
<th>REFERENCE NUMBER</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consult instructions for use</td>
<td>ISO 15223-1 Medical Devices - Symbols to be used with medical device labels - General requirements</td>
<td>Section 5.4.3</td>
<td>Indicates the need for the user to consult the instructions for use.</td>
<td></td>
</tr>
<tr>
<td>Caution</td>
<td>ISO 15223-1 Medical Devices - Symbols to be used with medical device labels - General requirements</td>
<td>Section 5.4.4</td>
<td>Indicates the need for the user to consult the instructions for use for important cautionary information such as warnings and precautions that cannot, for a variety of reasons, be presented on the medical device itself.</td>
<td></td>
</tr>
<tr>
<td>In vitro diagnostic medical device</td>
<td>ISO 15223-1 Medical Devices - Symbols to be used with medical device labels - General requirements</td>
<td>Section 5.5.1</td>
<td>Indicates a medical device that is intended to be used as an in vitro diagnostic medical device.</td>
<td></td>
</tr>
<tr>
<td>Do not reuse</td>
<td>ISO 15223-1 Medical Devices - Symbols to be used with medical device labels - General requirements</td>
<td>Section 5.4.2</td>
<td>Indicates a medical device that is intended for one use, or for use on a single patient during a single procedure.</td>
<td></td>
</tr>
<tr>
<td>LOT</td>
<td>Batch code</td>
<td>ISO 15223-1 Medical Devices - Symbols to be used with medical device labels - General requirements</td>
<td>Section 5.1.5</td>
<td>Indicates the manufacturer’s batch code so that the batch or lot can be identified.</td>
</tr>
<tr>
<td>EXP</td>
<td>Use-by date</td>
<td>ISO 15223-1 Medical Devices - Symbols to be used with medical device labels - General requirements</td>
<td>Section 5.1.4</td>
<td>Indicates the date after which the medical device is not to be used.</td>
</tr>
</tbody>
</table>

General Questions? Call 1-800-777-4908
Technical Support? Call 1-800-526-2125

Satisfaction Guaranteed
If you are not completely satisfied with any McKesson brands product, you may return it for a full refund or credit.

Distributed by McKesson Medical-Surgical Inc.
Richmond, VA 23233
PVN A0717 P-52641
Made in USA